Table 3.
Risk of SI according to age
| DMARD |
Anti-TNF |
||||||
|---|---|---|---|---|---|---|---|
| Age band, years | Follow-up, pyrs | Infections (n) | Events/1000 pyrs (95% CI) | Follow-up, pyrs | Infections (n) | Events/1000 pyrs (95% CI) | AdjHRa,b (95% CI) |
| <55 | 2951 | 52 | 18 (13, 23) | 17 100 | 477 | 28 (25, 31) | 1.2 (0.8, 1.6) |
| 55–64 | 2964 | 76 | 26 (20, 32) | 11 608 | 533 | 46 (42, 50) | 1.4 (1.1, 1.9) |
| 65–74 | 2414 | 125 | 52 (43, 62) | 6325 | 395 | 62 (56, 69) | 0.9 (0.7, 1.2) |
| >75 | 931 | 43 | 46 (33, 62) | 1198 | 99 | 83 (67, 101) | 1.5 (0.9, 2.6) |
aAdjusted for age, gender, COPD, diabetes, smoking, disease duration, DAS, HAQ, entry year, steroid use and MTX use. bWald test for significance between groups confirms non-significance (P = 0.210). pyrs: patient-years.